[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurodevelopmental-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurodevelopmental-disorders":36},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,79,0,25,[9,57,95,124,150,174,207,238,268,292,328,354,383,407,427,449,480,545,569,592,628,648,668,695,723],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":38,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100472474","rett-syndrome-registry-100472474",false,"NCT05432349","Rett Syndrome Registry","Rett Syndrome Real World Data Observational Registry","RSR","Inclusion Criteria:\n\n* Male or female with a pathologic loss of function alteration of MECP2\n\nExclusion Criteria:\n\n* Male or female with a gain of function alteration of MECP2, including those with MEPC2 duplication or triplication","ALL","0 Years","99 Years",{"count":22,"type":23},3000,"ESTIMATED","5 Years","OBSERVATIONAL","The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett syndrome and to facilitate the development of better clinical trials and other aspects of the drug development path for Rett syndrome.",[28,29,30,31,32,33,34,35,36,37],"Rett Syndrome","Rett Syndrome, Atypical","Genetic Disease","Genetic Diseases, X-Linked","Intellectual Disability","Neurobehavioral Manifestations","Neurologic Manifestations","Neurologic Disorder","Neurodevelopmental Disorders","Nervous System Diseases",[39,40,41,42,43],"Rett syndrome","MECP2","Neurodevelopmental disorder","Registry","Natural History Study","RECRUITING","2026-06-26",{"date":47,"type":48},"2026-06-30","ACTUAL",{"date":50,"type":48},"2022-08-02",{"date":52,"type":23},"2028-07",{"name":54,"class":55},"International Rett Syndrome Foundation","OTHER",19,{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":18,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":78,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100551076","the-genetics-navigator-evaluating-a-digital-platform-for-genomics-health-services-100551076","NCT06455384","The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services","Inclusion:\n\n* Adult patients (18 years of age or older) who are referred to participating clinicians at Mount Sinai Hospital for clinical genetic testing.\n* Parents\u002Flegal guardians (18 years of age or older) of pediatric patients who are referred to participating clinicians at SickKids for clinical genetic testing.\n\nExclusion:\n\n* Known not to be eligible for clinical genetic testing in Ontario\n* Requires urgent clinical genetic testing or prenatal genetic testing\n* Not fluent in English (speaking and reading)",true,"18 Years",{"count":66,"type":23},170,"INTERVENTIONAL",[69],"NA","Genetic testing (GT) (including targeted panels, exome and genome sequencing) is increasingly being used for patient care as it improves diagnosis and health outcomes. In spite of these benefits, genetic testing is a complex and costly health service. This results in unequal access, increased wait times and inconsistencies in care. The use of e-health tools to support genetic testing delivery can result in a better patient experience and reduced distress associated with waiting for results and empower patients to receive and act on medical results. We have previously developed and tested an interactive, adaptable and patient-centred digital decision support tool (Genetics ADvISER) to be used for genetic testing decision making, and have now developed the Genetics Navigator (GN), a patient-centred e-health navigation platform for end-to-end genetic service delivery. The objective of this study is to evaluate the effectiveness of the GN in an RCT in reducing distress with patients and parents of patients being offered genetic testing. Results of this trial will be used to establish whether the GN is effective to use in practice. If effective, GN could fill a critical clinical care gap and improve health outcomes and service use by reducing counselling burden as well as overuse, underuse and misuse of services. These are concerns policy makers seek to address through the triple aims of health care1. This study represents a significant advance in personalized health by assessing the effectiveness of this novel, comprehensive e-health platform to ultimately improve genetic service delivery, accessibility, patient experiences, and patient outcomes.",[72,73,74,75,36,76,77],"Cardiac Conditions","Connective Tissue Diseases","Retinal Disease","Epilepsy in Children","Cancer","Polyposis",[79,80,81,82,83,84],"Genomic Sequencing","Randomized Controlled Trial","Clinical Utility","Personal Utility","Decision Aid","Incidental Findings","2026-06-19",{"date":87,"type":48},"2026-06-24",{"date":89,"type":48},"2025-10-28",{"date":91,"type":23},"2027-07",{"name":93,"class":55},"Unity Health Toronto",3,{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":63,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100491653","platform-for-the-prospective-mother-child-study-of-the-determinants-of-neurodevelopmental-disorders-100491653","NCT05681923","Platform for the Prospective Mother-child Study of the Determinants of Neurodevelopmental Disorders","Platform for the Prospective Mother-child Study of the Determinants of Autism Spectrum Disorder and Neurodevelopmental Disorders Neurodevelopmental Disorders","MARIANNE","INCLUSION CRITERIA:\n\nGeneral inclusion criteria (High risk and Low risk cohorts)\n\nMother:\n\n* Be pregnant (single or multiple pregnancy), at least 16 weeks of amenorrhea,\n* Have at least one biological child of 24 months or older,\n* At least 18 years of age\n\nFather:\n\n* Be the biological father of the unborn child,\n* At least 18 years of age\n\nUnborn Child:\n\n\\- Have a woman study participant as mother.\n\nSpecific inclusion criteria for the High risk cohort:\n\n* Autistic sibling: refers to the biological child(ren) of the mother and\u002For father participating in the study and being the parent(s) of the unborn child\n* Be at least 24 months old and less than 18 years old,\n* Have a confirmed diagnosis of Autism Spectrum Disorder based on medical records. If in doubt, the SRS-2 (Social Responsiveness Scale for Adults) and PEDS-DM (Parents' Evaluation of developmental status) questionnaires will be completed. Only children with positive scores on one of these questionnaires will be included after validation of the diagnosis by an expert committee,\n* In case of several children with Autism Spectrum Disorder based in the siblings, only the last born will be included.\n\nRemarks:\n\n* Autism Spectrum Disorder siblings resulting from a medically assisted procreation are eligible provided that part of the genetic heritage is common to that of the mother or father of the unborn child participating in the study.\n* If the father does not live with the mother of the unborn child, his participation is not required and does not preclude the participation of other family members.\n\nEXCLUSION CRITERIA:\n\nGeneral non-inclusion criteria (High risk and Low risk cohorts):\n\nFather and mother:\n\n* Unable to understand French or the study questionnaires\n* Participant on protective measures (guardianship or curatorship) or deprived of liberty by judicial or administrative decision, or subject to a legal protection measure\n* Not affiliated to a social security system\n* Refusal to participate. In the case of consent given for the born and unborn child, the consent must be given by the person(s) with parental authority.\n* Live at a distance from the recruitment center incompatible with follow-up.\n\nSpecific non-inclusion criteria for the Low risk cohort:\n\nMother and\u002For father of unborn child:\n\n\\- Have a biological child with a diagnosis of Autism Spectrum Disorder or other neuro developmental disorder",{"count":104,"type":23},7320,"Neurodevelopmental disorders such as attention deficit disorder with or without hyperactivity, autism spectrum disorder, language and social communication disorder, motor coordination disorder, learning disorder (dyslexia, dyscalculia, dysorthography), intellectual development disorder are frequent and long-lasting developmental difficulties that can be observed in children in various domains. They are often associated and have a significant impact on daily functioning at school and at home.\n\nThe rate of people affected by neurodevelopmental disorders including autism spectrum disorder have increased significantly over the past 20 years. Improved screening only partly explains this evolution.\n\nA genetic predisposition plays an important role in the occurrence of these disorders, however, current scientific data suggest a multifactorial origin. Exposures such as those related to the use of pesticides, air pollution or the presence of endocrine disruptors in our diet could be involved in the genesis of neurodevelopmental disorders, particularly during intrauterine life, a period of great vulnerability.\n\nThe current diagnostic pathways for autism rarely enable the early identification of babies at risk. Without early detection and timely targeted intervention, these children have a poor health outcome and do not reach their full potential.\n\nThe general objective of the MARIANNE cohort is to constitute a French research infrastructure dedicated to research on the biological and environmental determinants of neurodevelopmental disorders including autism.\n\nThis cohort is based on the follow-up of 1200 families with already a child affected by an autism spectrum disorder, which implies a high risk of neurodevelopmental disorders including autism spectrum disorder for the siblings, and of 500 families from the general population with no excess risk of neurodevelopmental disorders. The total number of subjects to be included (mother, father, unborn child and ASD sibling for the HR group) is thus 6300.\n\nThe inclusion of these families will be at the beginning of a new pregnancy and the follow-up will be carried out from the second trimester of pregnancy until the children are 6 years old, the age at which the diagnosis of neurodevelopmental disorders is possible.\n\nBiological, clinical, social and environmental data will be collected at different stages of the follow-up and will be included into a large database.",[107,36],"Autism Spectrum Disorder",[109,110,111,112,113],"exposome","child development","genome","risk factors","prenatal cohort","2026-06-18",{"date":116,"type":48},"2026-06-22",{"date":118,"type":48},"2023-04-19",{"date":120,"type":23},"2034-03",{"name":122,"class":55},"University Hospital, Montpellier",1,{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":63,"sex":18,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":123},"100634691","individual-neurophysiological-sensory-profiles-in-people-with-and-without-neurodevelopmental-disorders-100634691","NCT07542977","Individual Neurophysiological Sensory Profiles in People With and Without Neurodevelopmental Disorders","SensAUry","Inclusion Criteria:\n\n* Social security affiliation\n* Free and written informed consent from the participants (Neurotypical Adults, NDD Adults without judicial protective measures), or their tutor or legal representant(s) (other participants)\n* Age between 6 and 12 years included (Children) or between 18 and 45 years included (Adults)\n* For NDD participants: NDD diagnosis by a qualified medical professional, according to DSM-4, DSM-5, ICD-10 or ICD-11 criteria\n\nNon-inclusion Criteria:\n\n* Psychotropic medication perturbing EEG recording\n* Drugs pertubing peripheral neurophysiological measures\n* Non-corrected visual or auditory troubles\n* Known neurological or psychiatric conditions (at the exclusion of NDD for NDD participants)\n* Epilepsy\n* Inclusion in another ongoing medical protocol\n* For Neurotypical participants: NDD diagnosis\n* For NDD participants: anticipated psychological or physical risk at participating, at the investigator's discretion\n\nExclusion Criteria:\n\n* Participants with no data to evaluate Outcome 1","6 Years","45 Years",{"count":134,"type":23},200,"The goal of this observational study is to evaluate intra-individual neurophysiological variability in children and adults with and without NeuroDevelopmental Disorders (NDD), for several sensory modalities and types of stimulation. The main hypotheses are:\n\n* NDD participants and children exhibit higher intra-individual variability than other participants\n* intra-individual neurophysiological variability is correlated to behavioral, psychological and learning profiles\n\nParticipants in this study will:\n\n* be recorded for EEG and other neurophysiological parameters while exposed to sensory stimulations, to quantify sensory neurophysiological variability\n* perform behavioral tests and fill out questionnaires, to establish the behavioral and psychological profile\n* train for perceptual learning, to measure learning abilities\n\nThese evaluations will be split in 3 visits spread on a maximum of 3 months, and training for learning will be done at home in between 2 visits.",[36],[138,139,140],"Sensory","Neurophysiology","Profile","2026-06-12",{"date":143,"type":48},"2026-06-16",{"date":145,"type":48},"2026-05-07",{"date":147,"type":23},"2028-06-15",{"name":149,"class":55},"University Hospital, Tours",{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":18,"minAge":64,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":67,"phases":161,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":123},"100582945","homelessness-and-prevalence-of-neurodevelopmental-disorders-100582945","NCT06869915","Homelessness and Prevalence of Neurodevelopmental Disorders","Prevalence of Neurodevelopmental Disorders in a Homeless Population - Pilot Study","PRECA'TND","Inclusion Criteria:\n\n* Homeless people sheltered in accommodation and social rehabilitation centers\n* Over 18 years of age\n* Who speak French\n* who have given then written informed consent\n\nExclusion Criteria:\n\n\\- Every person who hasn't given their written informed consent.","90 Years",{"count":160,"type":23},150,[69],"Introduction \\& Central question: Psychiatric disorders are highly prevalent in the homeless population, however neurodevelopmental disorders are also at risk of leading to homelessness (Churchard et al., 2018; Casey et al., 2020). Research on this topic is poor in France. This research aims to study the prevalence in France of 3 neurodevelopmental disorders (NDDs) in a homeless population (Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Intellectual Developmental Disorder).\n\nMethods \u002F approach: A 2 phase approach will be used including a screening phase and a diagnosis phase. This research is a pilot study that will include 150 homeless people, over 2 years. The assessment involves combining the results from standardised self-report tools, direct observation and informant-report, thus guaranteeing an objective and thorough diagnosis. This approach gives a better picture of actual behaviour but also a better understanding of the person's development.\n\nOUTCOME: This study will give insight on how to better understand the profile of the homeless population in France, and the prevalence of autism in this population. It will also bring valuable knowledge on how autism and other NDDs can impact one's path in life and lead to homelessness. The results can help develop targeted cares and measures for homeless people with NDDs.",[36],[165],"homelessness","2026-06-10",{"date":141,"type":48},{"date":169,"type":48},"2026-03-09",{"date":171,"type":23},"2027-09-30",{"name":173,"class":55},"Hôpital le Vinatier",{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":181,"minAge":64,"maxAge":182,"enrollmentInfo":183,"targetDuration":185,"studyType":25,"phases":4,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100436511","neuraxial-labor-analgesia-and-offspring-neurodevelopment-100436511","NCT04964206","Neuraxial Labor Analgesia and Offspring Neurodevelopment","Impact of Maternal Neuraxial Labor Analgesia on Offspring Neurodevelopment. A Multicenter, Prospective, Longitudinal Cohort Study","Inclusion Criteria:\n\n1. Primiparae between 18 and 35 years of age with term single cephalic pregnancy;\n2. Undergo regular prenatal examination in the study centers;\n3. Preparing to deliver vaginally.\n\nExclusion Criteria:\n\n1. History of psychiatric diseases (indicate those that are diagnosed before or during pregnancy by psychiatrists);\n2. History of diseases involving the hypothalamic-pituitary-adrenal axis;\n3. Presence of contraindications to epidural analgesia, which includes: (1) History of infectious disease of the central nervous system (poliomyelitis, cerebrospinal meningitis, encephalitis, etc.); (2) History of spinal or intra-spinal disease (trauma or surgery of spinal column, intra-spinal canal mass, etc.); (3) Systemic infection (sepsis); (4) Skin or soft tissue infection at the site of epidural puncture; (5) Coagulopathy.\n4. Presence of contraindications to vaginal delivery;\n5. Other reasons that are considered unsuitable for study participation.","FEMALE","35 Years",{"count":184,"type":23},4645,"24 Months","How perinatal factors affect the long-term development of children has always been an issue of much concern. This study is designed to explore the potential impact of maternal neuraxial labor analgesia exposure on offspring neurodevelopment.",[188,189,190,191,36],"Pregnant Women","Labor Pain","Analgesia, Epidural","Infants",[193,194,195,191,196],"Pregnant women","Labor pain","Neuraxial labour analgesia","Neurodevelopmental disorders","2026-06-05",{"date":199,"type":48},"2026-06-09",{"date":201,"type":48},"2022-10-14",{"date":203,"type":23},"2028-12",{"name":205,"class":55},"Dong-Xin Wang",2,{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":214,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":67,"phases":218,"briefSummary":219,"conditions":220,"keywords":223,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":123},"100640203","probiotics-supplementation-for-neurodevelopment-in-preterm-infants-100640203","NCT07617181","Probiotics Supplementation for Neurodevelopment in Preterm Infants","Effect of Gut Microbiota Remodeling Via Probiotics Supplementation on Neurodevelopment in Preterm Infants: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Preterm infants with a gestational age between 28 and 37 weeks (inclusive of 28 weeks)\n* Documented history of neonatal intravenous antibiotic exposure for at least 5 consecutive days during the neonatal period (e.g., in the NICU).\n* Corrected age of 6 months ± 7days at the time of enrollment.\n* No systemic antibiotic usage within 14 days prior to screening.\n* Legal guardians are willing to sign the informed consent form and comply with the 6-month intervention and follow-up schedule.\n\nExclusion Criteria:\n\n* Severe congenital malformations, chromosomal abnormalities, or inherited metabolic diseases (e.g., Down syndrome).\n* Severe neurological disorders or structural brain injuries (e.g., Grade III\u002FIV intraventricular hemorrhage, cystic periventricular leukomalacia, or hydrocephalus requiring a shunt).\n* Severe chronic diseases affecting growth and development (e.g., congenital heart disease requiring surgery, short bowel syndrome, or severe sequelae of necrotizing enterocolitis).\n* Concurrent participation in other interventional clinical trials.\n* Planned long-term use of other commercial probiotic\u002Fprebiotic supplements outside the study protocol during the intervention period.\n* High risk of loss to follow-up (e.g., expected relocation).","23 Weeks","25 Weeks",{"count":217,"type":23},116,[69],"The purpose of this randomized controlled trial is to evaluate the effect of daily supplementation with a probiotic mixture on the neurodevelopmental outcomes of preterm infants with a history of neonatal antibiotic exposure. The intervention lasts for 6 months. The study hypothesizes that early gut microbiota remodeling via exogenous probiotics can improve neurodevelopment. The primary outcome is assessed by the Gesell Developmental Schedules or the Ages \\& Stages Questionnaires (ASQ-3). Secondary outcomes include longitudinal changes in gut microbiota composition,targeted metabolomics (such as short-chain fatty acids \\[SCFAs\\], and systemic inflammatory markers.",[221,36,222],"Premature Birth","Dysbiosis",[224,225,226,227],"Probiotics","Gut-Brain Axis","Neonatal Antibiotic Exposure","Preterm Infants","NOT_YET_RECRUITING","2026-05-23",{"date":231,"type":48},"2026-06-01",{"date":233,"type":23},"2026-06",{"date":235,"type":23},"2027-12",{"name":237,"class":55},"Fudan University",{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":206},"100435641","perinatal-covid-19-infection-no-pathway-and-minipuberty-100435641","NCT04952870","Perinatal Covid-19 Infection, NO Pathway, and Minipuberty","Exploratory Multicenter Observational Study to Assess the Outcome of Infants With Perinatal SARS-COV-2 Infection and Its Link With the NO Pathway: the Minipuberty Hypothesis","miniNO-COVID","Inclusion Criteria:\n\n* Group 1 : Newborn infants (24 to 41 weeks gestational age) or young infants (\\\u003C 3 months) admitted at the maternity ward or at the Department of Neonatology at Jeanne de Flandre Hospital, CHU of Lille with perinatal COVID-19 infection defined by:\n\n  * Antenatal COVID-19 infection: pregnant women with positive PCR test at any time of the pregnancy;\n  * Post-natal COVID-19 infection: newborn or young infants (\\\u003C 3 months) with positive PCR test in pharynx or stools as part of their treatment.\n* Group 2 : Newborn infants (24 to 41 weeks gestational age) or young infants (\\\u003C 3 months) admitted at the maternity ward or at the Department of Neonatology at Jeanne de Flandre Hospital, CHU of Lille for severe cardiorespiratory diseases requiring inhaled NO treatment.\n* Group 3 : The control group without perinatal COVID-19 infection and no inhaled NO treatment will be matched to the two other groups on age at birth (± 2 weeks of gestation), on postnatal age (± 3 weeks), on respiratory failure (yes\u002Fno).\n* No inclusion in another ante- or post-natal trial;\n* Written consents from both parents.\n* Social security affiliation\n\nExclusion Criteria:\n\n* Preterm birth less than 24 weeks gestational age.\n* Severe brain lesions: bilateral and extensive periventricular leukomalacia, intracranial hemorrhage grade 3 or 4;\n* One or both of the parents is unable to read or understand French language, or refuse to participate","3 Months",{"count":248,"type":23},180,"Some evidence exists that SARS-COV-2 may infect pituitary axis, and therefore may alter hypothalamic function. Whether perinatal COVID-19 is associated with alterations in the maturation of the Hypothalamic-Pituitary-Gonadal (HPG) axis, and specifically with its transient activation occurring during infancy, namely minipuberty, is a major concern. Among the various pathogenic features related to COVID-19, altered minipuberty could be a key factor underlying many multimorbidities later in life, suggesting that they could involve a common causative mechanism that occurs within this short and critical period of time following birth. Altered minipuberty together with NO deficiency seem to be key factors underlying many of these multimorbidities, suggesting that they involve a common causative mechanism that occurs within this short and critical period of time following birth",[251,36],"Newborn, Infant, Disease",[253,254,255,256,257,258],"Perinatal COVID","newborn","minipuberty","HPG axis","nitric oxide","neurodevelopmental outcome","2026-05-19",{"date":261,"type":48},"2026-05-20",{"date":263,"type":48},"2022-11-03",{"date":265,"type":23},"2026-11",{"name":267,"class":55},"University Hospital, Lille",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":67,"phases":279,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":123},"100622746","effectiveness-of-the-copca-program-in-infants-at-risk-of-neurodevelopmental-disorders-100622746","NCT07387627","Effectiveness of the COPCA Program in Infants at Risk of Neurodevelopmental Disorders","Effectiveness of the Coping With and Caring for Infants With Special Needs Program in Infants at Risk of Neurodevelopmental Disorders. A Comparison With Conventional Pediatric Physiotherapy Models and Parent Training","COPCA","Inclusion Criteria:\n\n* Infants at risk of neurodevelopmental disorders.\n* Participation in pediatric physiotherapy and\u002For Early Intervention programs at the time of study inclusion, regardless of the reference center.\n* Corrected age under 12 months at the time of recruitment.\n\nExclusion Criteria:\n\n* Infants with confirmed neurodevelopmental disorders at the time of inclusion.\n* Presence of additional medical conditions requiring complex medical or surgical interventions that could interfere with participation in the study (e.g., recent or planned surgery).\n* Severe family socio-communicative difficulties that limit participation in coaching sessions (e.g., significant language barriers).","12 Months",{"count":278,"type":23},40,[69],"The purpose of this clinical trial is to evaluate whether the COPCA® program (Coping with and Caring for Infants with Special Needs) is more effective than conventional pediatric physiotherapy and parent education in improving development in infants at risk of neurodevelopmental disorders, as well as empowering their families.\n\nThis study will include infants younger than 12 months of corrected age who are at risk of neurodevelopmental disorders and are currently receiving early intervention or pediatric physiotherapy services, together with their parents or primary caregivers.\n\nThe main questions this study aims to answer are:\n\nDoes the COPCA® program improve motor development and functional abilities in infants at risk of neurodevelopmental disorders more than conventional pediatric physiotherapy or parent education?\n\nDoes the COPCA® program increase family empowerment and improve parents' perception of the care they receive compared with traditional intervention models?\n\nThe researchers will compare outcomes across four study groups:\n\nIn-person COPCA® intervention\n\nOnline COPCA® intervention\n\nParent education group\n\nConventional pediatric physiotherapy group\n\nParticipants will be randomly assigned to one of the four groups. The intervention period will last 6 months, with assessments conducted at the start of the study, during the intervention, and during follow-up.\n\nInfants will take part in age-appropriate daily activities and play situations. Parents or caregivers will actively participate in the intervention sessions and will be supported in learning how to promote their child's development during everyday routines.\n\nThe study will assess infant motor development, functional abilities, overall development, family empowerment, and parents' perception of family-centered care using validated assessment tools and interviews. The results of this study may help improve early intervention strategies for infants at risk of neurodevelopmental disorders and support more family-centered approaches to care.",[36,282],"Neurodevelopmental Disorders and Developmental Abnormalities","2026-04-28",{"date":285,"type":48},"2026-04-29",{"date":287,"type":48},"2026-02-10",{"date":289,"type":23},"2027-06-01",{"name":291,"class":55},"University of Seville",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":300,"maxAge":64,"enrollmentInfo":301,"targetDuration":4,"studyType":67,"phases":303,"briefSummary":304,"conditions":305,"keywords":311,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":123},"100636006","a-scalable-trans-diagnostic-intervention-targeting-adolescent-agency-supported-by-conversational-ai-agencia-100636006","NCT07560072","A Scalable Trans Diagnostic Intervention Targeting Adolescent Agency Supported by Conversational AI (AGENCIA)","A Randomized Controlled Trial Protocol of a Scalable Trans Diagnostic Intervention Targeting Adolescent Agency Supported by Conversational AI","AGENCIA","Inclusion Criteria:\n\n* Adolescents aged 12 to 18 years at enrollment.\n* Presence of emotional or behavioral difficulties causing functional interference (e.g., irritability, impulsivity, emotional dysregulation, conflicts at home or school, avoidance).\n* Difficulties compatible with neurodevelopmental profiles, regardless of formal diagnosis.\n* Ability to use digital materials through a personal device and basic reading skills in Spanish.\n* Availability to attend assessments and participate in the intervention and follow-up schedule.\n* Informed consent from caregivers and assent from the adolescent.\n\nExclusion Criteria:\n\n* Acute clinical risk at pre-screening or screening (e.g., imminent self-harm risk, severe agitation, aggression, disorganized behavior, or unsafe behaviors requiring immediate clinical care).\n* Score of \"Severe\" on any of the three HoNOSCA screening items (self-harm, substance-related problems, or bullying\u002Fsocial problems).\n* Uncompensated sensory, motor, or language barriers preventing valid completion of assessments or participation (e.g., severe visual or hearing impairment, significant receptive\u002Fexpressive language difficulties, motor limitations preventing device use).\n* Intellectual disability defined by screening tools: ABAS-II GAC ≤ 70 or Kaufman Brief Intelligence Test Composite Intelligence Quotient ≤ 70.\n* Any condition judged by the clinical team to require immediate alternative care or that would prevent safe participation.","12 Years",{"count":302,"type":23},465,[69],"The aim of this clinical trial is to evaluate whether AGENCIA, a brief psychological program supported by digital technology and artificial intelligence, can help reduce emotional and behavioral difficulties in adolescents aged 12 to 18. These difficulties may include irritability, impulsive behaviors, conflicts at home or at school, or difficulties in managing intense emotions. The study also aims to determine whether the effects are similar across adolescents with different symptom profiles or neurodevelopmental characteristics.\n\nParticipants will be randomly assigned to one of three groups:\n\nAGENCIA Digital: a self-guided online version completed at home. AGENCIA in-person with a digital assistant: a clinician-delivered version supported by an interactive digital assistant to guide the exercises.\n\nDigital psychoeducation (control): a self-guided online program providing general information about adolescent well-being.\n\nThe main research questions are:\n\nDoes AGENCIA reduce overall emotional and behavioral difficulties? Does the program improve functioning, family accommodation, and personal agency (a young person's sense of being able to act and make changes)? Are the effects similar across adolescents with different profiles or neurodevelopmental characteristics?\n\nParticipants will:\n\n* Complete three structured sessions depending on their assigned group.\n* Complete brief online questionnaires at baseline (T0), immediately after the sessions (T1), and at 1-month (T2) and 6-month (T3) follow-ups.\n* Receive brief phone calls during follow-ups to support questionnaire completion.\n\nA total of 465 adolescents will take part in the study. Participation is voluntary and does not replace usual clinical care. The study does not involve medication or invasive procedures, and all digital tools operate within secure institutional systems.",[306,36,307,308,309,310],"Irritability","Impulsivity","Emotional Dysregulation","Distress, Emotional","Distress, Psychological",[312,313,314,315,196,316,317,318],"Adolescents","Randomized controlled trial","Personal Agency","Digital health intervention","Family accommodation","Conversational AI","Trans diagnostic interventions","2026-04-23",{"date":321,"type":48},"2026-04-30",{"date":323,"type":23},"2026-04-01",{"date":325,"type":23},"2028-12-31",{"name":327,"class":55},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla",{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":336,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":123},"100489887","kidsheart-and-brain--early-eeg-surgery-congenital-heart-disease-predict-onset-of-neurodevelopmental-disorders-100489887","NCT05658965","KIDSHEART AND BRAIN : Early EEG Surgery Congenital Heart Disease Predict Onset of Neurodevelopmental Disorders","Intérêt de l'électroencéphalogramme précoce en Chirurgie de Cardiopathie congénitale Pour prédire la Survenue de Troubles du neurodéveloppement","KHB","Inclusion Criteria:\n\n* Child of less than 1 year admitted for cardiac surgery on extracorporal circulation on the CHU of Lille during the study period.\n* Child with congenital cardiopathy with necessity to be operated before 1 year old.\n\nExclusion Criteria:\n\n* Child with no necessity of surgery before 1 year old.\n* Medical history of cardiac surgery.\n* Refusal of consent by the parents.\n* No social security.\n* Child not operated on the CHU of LILLE.","1 Day","1 Year",{"count":339,"type":23},50,"Congenital cardiopathy are frequent malformations (1\u002F100 birth). The progress of surgery permit a survival rate at the adult age of more than 90%. The long terms consequences must be taken in account and the nerodevelopmental disorders are in first place (intelectual deficiency, autism spectrum disorders, or attention disorders) and presents in 30 to 60% of the patients (Calmant, 2015). The impact can be important on the scolarity, the studies, the professional activity and finaly on the quality of life of the patients becomming adults.\n\nThe identification of the risk factors on surgery period should permit to propose the most adapted follow-up to the specifics needs of each patients.\n\nOn the scientific plans, the identification of early markers on brain dammage on EEG should permit to better apprehend the physiopathologic mecanisms involved.",[36,342],"Congenital Cardiomyopathy",[344,36,342,345],"EEG","Orality Disorders","2026-04-21",{"date":348,"type":48},"2026-04-24",{"date":350,"type":48},"2022-10-10",{"date":352,"type":23},"2026-10-13",{"name":267,"class":55},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":361,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":67,"phases":365,"briefSummary":366,"conditions":367,"keywords":370,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":123},"100626718","characterization-of-social-cognition-profiles-in-children-and-adolescents-with-neurodevelopmental-disorders-a-clinical-study-using-a-multidimensional-battery-100626718","NCT07439276","Characterization of Social Cognition Profiles in Children and Adolescents With Neurodevelopmental Disorders: a Clinical Study Using a Multidimensional Battery","COGSO","Inclusion Criteria:\n\n* Children and adolescents aged 8 to 16 years\n* Proficiency in French (native language)\n* Information and consent obtained from those holding parental authority, and agreement from the child or adolescent\n* No recently modified (\\\u003C6 weeks) psychotropic medication from the following categories: antidepressants, anxiolytics, antipsychotics, psychostimulants, mood stabilizers.\n* IQ above 70 (WISC-V)\n* Criteria for Neurodevelopmental Disorders: Diagnosis of Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder (according to DSM-5)\n* Multiple complex developmental disorder : Symptoms characteristic of a neurodevelopmental disorder without meeting all the criteria for a specific disorder and presence of multiple complex developmental disorder criteria with at least 5 elements from the specified categories.\n\nExclusion Criteria:\n\n\\- Having an active neurological disorder (e.g., active epilepsy)","8 Years","16 Years",{"count":364,"type":23},100,[69],"In France, more than one in ten school-aged children suffers from a mental health disorder, and half of these disorders appear before the age of 14. Yet, only half of affected children receive appropriate support. At the cognitive level, it is now widely accepted by the scientific community that strong socio-cognitive skills protect against the emergence of certain disorders. Social cognition skills, crucial for development and social integration, are often underestimated in clinical neuropsychology, particularly due to the lack of validated assessment tools for children.\n\nThe challenges related to the clinical assessment of social cognition in children and adolescents are therefore significant, especially since specific deficits are likely to be associated with numerous developmental pathologies and psychiatric disorders (neurodevelopmental disorders, mood disorders, anxiety disorders, psychotic disorders). However, these disorders are insufficiently assessed. A more precise characterization would allow for the identification of therapeutic targets specific to each neurodevelopmental disorder.\n\nTherefore, this research aims to address this lack of tools by using a multidimensional assessment battery of social cognition in children and adolescents aged 8 to 16, evaluating four fundamental domains of social cognition: emotion processing, social perception, theory of mind, and attributional style. This multidimensional assessment battery of social cognition is developed by the Child and Adolescent Psychiatry Department of Necker-Enfants Malades Hospital.",[36,107,368,369],"Attention Deficit Hyperactivity Disorder","Atypical Neurodevelopmental Disorder",[196,107,368,371,372,373],"Atypical neurodevelopmental disorder","Social cognition","Children and teenagers","2026-04-13",{"date":376,"type":48},"2026-04-16",{"date":378,"type":48},"2026-04-08",{"date":380,"type":23},"2029-04",{"name":382,"class":55},"Assistance Publique - Hôpitaux de Paris",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":123},"100532460","patterns-of-neurodevelopmental-disorders-100532460","NCT06213090","Patterns of Neurodevelopmental Disorders","Patterns of Disease, Outcomes and Treatment Response in Children With Neurodevelopmental Disorders","Inclusion Criteria:\n\nNeurodevelopmental delays Clinical visit at an Rossignol Medical Center\n\nExclusion Criteria:\n\n\\-",{"count":391,"type":23},1000,"The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.",[36,107,394,395,396,397,398,399],"Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection","Pediatric Acute-Onset Neuropsychiatric Syndrome","Down Syndrome","Epilepsy","Mitochondrial Encephalomyopathies","Cerebral Folate Deficiency",{"date":376,"type":48},{"date":402,"type":48},"2024-02-01",{"date":404,"type":23},"2030-12-31",{"name":406,"class":55},"Richard Frye",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":423,"leadSponsor":425,"locationsCount":4},"100630786","high-depth-exome-sequencing-on-dna-from-a-salivary-sample-by-mouth-smear-100630786","NCT07492199","High Depth Exome Sequencing on DNA From a Salivary Sample by Mouth Smear.","Evaluation of the Diagnostic Performance of High-depth Exome Sequencing on DNA From a Salivary Sample by Oral Smear in the Etiological Assessment of Patients With a Syndromic Neurodevelopmental Disorder or an Intellectual Development Disorder and for Which the Sequencing of the Genome on Blood Has Proved Inconclusive.","SEPASA","Inclusion Criteria:\n\n* Patient with syndromic neurodevelopmental disorder (NDD) or intellectual developmental disorder (IDD)\n* Trio genome sequencing on blood inconclusive\n* Men and women\n* All ages\n* No objection to participating in the study\n* Affiliation with a French social security system or beneficiary of such a system\n\nExclusion Criteria:\n\n* Pregnant women and nursing mothers\n* Persons deprived of their liberty by judicial or administrative decision; persons undergoing compulsory psychiatric care; persons admitted to a health or social care facility for purposes other than research\n* Subjects who are in the exclusion period of another study or listed in the \"national volunteer registry\"\n* Genetic cause identified in the preliminary etiological assessment\n* Phenocopy: other likely non-genetic cause of TND (perinatal anoxia, infection, trauma, etc.)\n* Patients without health insurance\n* Patients unlikely to cooperate with the study and\u002For anticipated low cooperation by the investigator",{"count":339,"type":23},"Despite technological advances, a genetic etiology has been identified in only about 50% to 60% of patients with Neurodevelopmental disorders (NDDs), with a higher diagnostic yield in the syndromic NDD and IDD subgroups. However, identifying a precise etiological diagnosis is essential to optimize patient care, clarify their prognosis, consider targeted therapies, refer families to appropriate resources and support, and provide genetic counseling to relatives. The tests typically offered as part of the etiological assessment of syndromic NDDs and IDD include DNA microarray analysis, testing for fragile X syndrome and genome sequencing from a blood sample. When this assessment remains negative, the cause usually remains unknown.\n\nMosaic genomic abnormalities (or post-zygotic variations) are a common cause of negative results in current diagnostic genetic tests and represent a field of research that has yet to be fully explored outside of skin disorders. Identifying mosaic genomic abnormalities remains technically complex due to the difficulty of detecting low levels of mosaicism and limited access to the tissue of interest when the variation is absent from blood tissue.\n\nHigh-depth exome sequencing is the technique of choice for detecting low levels of mosaicism. In the case of NNDs, as the affected tissue is not available, the buccal epithelium is an interesting alternative to blood, as it is easily accessible and inexpensive.\n\nThe objective of our study is to evaluate the diagnostic yield of high-depth exome sequencing technology on a DNA extracted from a buccal swab in the etiological assessment of patients with IDD or syndromic NDD whose reference analysis (genome sequencing on blood) proved inconclusive.",[36,418],"Intellectual Developmental Disorder","2026-04-09",{"date":421,"type":48},"2026-04-14",{"date":323,"type":23},{"date":424,"type":23},"2029-04-01",{"name":426,"class":55},"Centre Hospitalier Universitaire de Besancon",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":63,"sex":18,"minAge":434,"maxAge":131,"enrollmentInfo":435,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":437,"conditions":438,"keywords":439,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":447,"locationsCount":123},"100631624","the-relationship-between-reaction-time-and-motor-skills-in-children-with-pervasive-developmental-disorders-100631624","NCT07503106","The Relationship Between Reaction Time and Motor Skills in Children With Pervasive Developmental Disorders","The Relationship Between Reaction Time and Motor Skills in Preschool Children With Pervasive Developmental Disorders","Inclusion Criteria:\n\n* Being between 3 and 6 years of age\n* For typically developing children, having no diagnosis of any neurodevelopmental or orthopedic disorder\n* Having a diagnosis of Pervasive Developmental Disorder made by a child psychiatrist or pediatric neurologist\n* Absence of visual, auditory, or motor impairments that would prevent administration of the Peabody Developmental Motor Scales-2 (PDMS-2) and the Catch Pad reaction test\n* Having sufficient cognitive ability to understand and follow simple instructions during the assessment\n\nExclusion Criteria:\n\n* In the typically developing group, having a diagnosis of Attention Deficit -Hyperactivity Disorder (ADHD) or any other neurodevelopmental disorder\n* Presence of additional neurological or orthopedic conditions, apart from Pervasive Developmental Disorder, that would interfere with test administration\n* Visual or hearing impairments severe enough to prevent test administration\n* History of orthopedic trauma or surgery within the last 6 months that could affect motor performance\n* Presence of significant behavioral problems","3 Years",{"count":436,"type":23},30,"This study examines whether the relationship between reaction time and motor skills differs between children aged 3-6 with pervasive developmental disorders and typically developing peers. It aims to determine the direction and strength of this relationship in children with developmental disorders and compare it with that of typically developing children, thereby providing evidence on how cognitive processing speed and motor performance interact in early childhood under developmental disorder conditions.",[36],[440,441,442],"Reaction time","Peabody Developmental Motor Scales","Pervasive Developmental Disorders",{"date":374,"type":48},{"date":445,"type":23},"2026-04",{"date":233,"type":23},{"name":448,"class":55},"Yeditepe University",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":460,"conditions":461,"keywords":465,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":123},"100578123","motor-voice-assessment-in-infants-mami-100578123","NCT06807203","Motor-voice Assessment in Infants (MAMI)","Spontaneous Motor-voice Assessment in Infants Using Video and Audio Recordings.","MAMI","Inclusion Criteria:\n\n* gestational age of 24 0\u002F7 - 41 6\u002F7,\n* admitted to the NICU,\n* medically stable by 40 weeks of gestation (including off ventilator support),\n* born to mothers 18 - 43 years old at the time of birth,\n* one parent fluent in English.\n\nExclusion Criteria:\n\n* diagnosis of a genetic syndrome (e.g. Trisomy 21),\n* musculoskeletal deformity,\n* failed hearing screen.","10 Days",{"count":459,"type":23},46,"The goal of this observational study is to discover features of normal and disordered motor-voice profiles that are biobehavioral markers of physical disability in infants.. The main questions it aims to answer are:\n\nIdentify voice factors among infants with newborn-detectable risk. Identify association between individual characteristics (Gestational age at birth, global function, motor-function) and voice factors.\n\nExamine unique features of voice production that are present in infants with high-risk for Cerebral Palsy (CP).\n\nParticipants will be asked to upload a 3-minute videos of their child at term-age, 3.5-, and 9-months of age.\n\nAt the 3.5-month and 9-month time point parents can choose to attend an optional in-person assessment with their child.",[462,463,464,36,107],"Cerebral Palsy Infantile","Pre-Term","Motor Delay",[466,467,468,469,470],"Digital health,","Motor assessment,","voice assessment,","cognition","neurodevelopment,","2026-03-24",{"date":473,"type":48},"2026-03-27",{"date":475,"type":48},"2025-10-22",{"date":477,"type":23},"2030-01-28",{"name":479,"class":55},"Ohio State University",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":488,"maxAge":300,"enrollmentInfo":489,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":490,"conditions":491,"keywords":511,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":123},"100630855","intensive-multimodal-neurorehabilitation-targeting-neuroplasticity-in-pediatric-neurodevelopmental-and-chromosomal-disorders-100630855","NCT07493096","Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders","Functional and Neurodevelopmental Outcomes Following Intensive Multimodal Neurorehabilitation in Pediatric Patients With Neurodevelopmental Disorders, Including Chromosomal Abnormalities","GEN-HOPE","Inclusion Criteria:\n\n* Pediatric participants between approximately 4 and 12 years of age at the time of enrollment.\n* Diagnosed with or presenting with neurodevelopmental, neurologic, or genetic conditions, including but not limited to:\n\n  * cerebral palsy\n  * autism spectrum disorder\n  * developmental delay\n  * hypoxic ischemic encephalopathy (HIE)\n  * traumatic brain injury\n  * sensory processing disorder\n  * chromosomal or genetic abnormalities\n  * Demonstrate functional impairments in one or more neurodevelopmental domains, including:\n* motor coordination or motor planning\n* sensory processing\n* attention or executive functioning\n* oculomotor or visual processing\n* communication\n* emotional or behavioral regulation\n* activities of daily living\n* Enrolled in and able to participate in a two-week intensive therapy program consisting of approximately 2.5 hours per day\u002F 5 days per week\n\n  * Able to complete baseline and post-program clinical assessment using clinician-observed or caregiver-reported measures.\n  * Parent or legal guardian able to provide informed consent and participate in reporting functional outcomes when applicable.\n\nExclusion Criteria:\n\n* Medical instability or acute medical condition that would prevent safe participation in an intensive therapy program.\n* Severe uncontrolled seizure activity or other neurologic condition that would interfere with participation in structured therapeutic activities, as determined by the treating clinician.\n* Behavioral or psychological conditions that would prevent safe engagement in the therapy environment despite appropriate support.\n* Inability to attend or complete the full two-week intensive program.\n* Lack of sufficient baseline or post-intervention data to assess change in functional performance.\n* Concurrent participation in another structured intervention or clinical study that would confound interpretation of functional outcomes, at the discretion of the investigator.","4 Years",{"count":364,"type":23},"This observational study evaluates functional and developmental outcomes in pediatric participants undergoing a two week intensive multimodal neurorehabilitation program. The program is designed for children with neurodevelopmental disorders, including but not limited to cerebral palsy, autism spectrum disorder, developmental delay, hypoxic ischemic encephalopathy (HIE), and chromosomal or genetic abnormalities.\n\nParticipants receive individualized therapy sessions for approximately 2.5 hours per day over a two week period. The intervention is not standardized but is tailored to each child's specific needs and may include components such as sensory integration, motor planning, reflex integration, oculomotor training, executive functioning activities, communication support, and other brain based therapeutic approaches.\n\nThe purpose of this study is to observe changes in functional abilities, including attention, motor coordination, emotional regulation, communication, and activities of daily living. Outcomes are assessed using clinician observation and parent reported changes before and after the intensive program, with limited follow-up when available.\n\nThis study does not assign participants to a specific treatment as part of a research protocol. Instead, it collects real world data from children already participating in a clinical therapy program to better understand potential benefits of intensive, individualized neurorehabilitation approaches.",[36,492,282,493,494,495,462,496,497,107,498,499,500,501,502,503,504,505,506,507,508,509,510],"Neurodevelopmental Disorders (NDD)","Developmental Delay (Disorder)","Cerebral Palsy (CP)","Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment","Cerebral Palsy Spastic Hemiplegic","Cerebral Palsy, Dyskinetic","Autism Spectrum Disorder (ASD","Hypoxic Ischemic Encephalopathy","Hypoxic Ischemic Encephalopathy (HIE)","Traumatic Brain Injury (TBI)","Sensory Processing Disorder","Chromosomal Abnormalities","Genetic Disorders","Down Syndrome (Trisomy 21)","Fragile X Syndrome (FXS)","RETT Syndrome With Proven MECP2 Mutation","Williams Syndrome","22q11.2 Deletion Syndrome","Sensorimotor Integration",[512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,36,530,531,532,533,534,535],"Photobiomodulation","Low-Level Laser Therapy","Vibration Therapy","Tactile Stimulation","Cognitive Training","Behavioral Therapy","Intensive Therapy","Pediatric Neurorehabilitation","Multimodal Therapy","Neuroplasticity","Sensory Integration","Reflex Integration","Motor Planning","Executive Function","Emotional Regulation","Functional Outcomes","Activities of Daily Living","High Frequency Therapy","Rehabilitation","Child Development Disorders","Occupational Therapy","Physical Therapy Modalities","Early Intervention","Cognitive Therapy","2026-03-19",{"date":538,"type":48},"2026-03-25",{"date":540,"type":48},"2026-03-01",{"date":542,"type":23},"2036-12-30",{"name":544,"class":55},"Healing Hope International",{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":552,"maxAge":553,"enrollmentInfo":554,"targetDuration":4,"studyType":67,"phases":556,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":123},"100586446","phase-3-reducing-missed-appointments-100586446","NCT06915480","Reducing Missed Appointments","Reducing Appointment NoShow Through Targeted Pre-appointment Messaging","Inclusion Criteria:\n\n* All patients who are scheduled to be seen within the center for autism or the center for neuropsychological and psychological assessment for evaluation appointments will be automatically enrolled in the reminder message portion of the intervention trial.\n* Patients who are at elevated risk within the center for neuropsychological and psychological assessment are automatically enrolled in the patient navigator portion of the intervention trial.\n\nExclusion criteria:\n\n* None for the messaging portion of the study\n* For patient navigation, patients \\>18 years of age will be excluded.","1 Month","24 Years",{"count":555,"type":23},5000,[557],"PHASE3","There are four goals of this project: (1) To examine the impact of different appointment reminder messages on appointment attendance; (2) to determine the added benefit of a patient navigator reaching out in advance of appointments to families at elevated risk of missing their appointment, and determine the most common barriers families face in appointment attendance; (3) to evaluate which patients are at highest risk of missing their appointment, and to determine the effectiveness of the intervention trial across different patient risk levels; and (4) to examine if the missing appointment interventions increase the socioeconomic diversity patients.",[36],"2026-03-17",{"date":562,"type":48},"2026-03-18",{"date":564,"type":48},"2025-12-29",{"date":566,"type":23},"2027-12-01",{"name":568,"class":55},"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":18,"minAge":434,"maxAge":576,"enrollmentInfo":577,"targetDuration":4,"studyType":67,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":123},"100543156","effect-of-probiotics-on-the-intestinal-microbiota-of-pediatric-patients-100543156","NCT06352203","Effect of Probiotics on the Intestinal Microbiota of Pediatric Patients","Randomized, Double-blind, Placebo-controlled Study to Evaluate the Modulating Effect of Probiotics on the Intestinal Microbiota of Pediatric Patients With Neurodevelopmental Disorders.","Inclusion Criteria:\n\n* Children aged 3 to 7 years old.\n* Diagnosed with autism spectrum disorder, according to the clinical criteria of the \"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)\" and who meet criteria for ASD according to the ADOS-2 classification.\n* Presenting one or more gastrointestinal symptoms (constipation, diarrhoea, abnormal stools, painful defecation, abdominal pain, reflux, bloating, flatulence).\n* Written informed consent signed by the parent or legal guardian with express or tacit consent of the other parent.\n\nExclusion Criteria:\n\n* With intake of antibiotics in the last month.\n* With intake of probiotics in the last two weeks.\n* Diagnosed with short bowel syndrome or has undergone relevant surgery on the gastrointestinal tract.\n* Exhibiting a defect in the intestinal epithelial barrier (e.g. inflammatory bowel disease (IBD)).\n* Diagnosed with endocrinological diseases such as diabetes mellitus, hypo- and hyperthyroidism, Cushing's disease, Addison's disease, etc.\n* Having heart failure and a cardiac medical history (e.g. artificial heart valve, medical history of infective endocarditis, rheumatic fever, or cardiac malformation).\n* Congenital or acquired immunodeficiency.\n* Immunocompromised (e.g., cancer and\u002For transplant patients taking certain immunosuppressive drugs, patients with inherited diseases that affect or may affect the immune system).\n* Uncertainty on the part of the investigator about the willingness or ability of the minor's parents or legal guardian to comply with the requirements of the protocol.\n* With oral hyper sensitivity impairments that prevent the uptake of the study product.","7 Years",{"count":578,"type":23},60,[69],"Numerous studies have described an altered gut microbiota composition (dysbiosis) in patients with neurodevelopmental disorders that can be correlated with their symptoms, especially gastrointestinal symptoms.\n\nAn interventional, randomised, double-blind, placebo-controlled study will be conducted to investigate the effect of a probiotic supplement on the microbiota composition of children aged 3-7 years with neurodevelopmental issues.\n\nThe duration of the study will be of 6 months approximately, including 6 months of product intake.\n\nParticipants will be randomly assigned to one of the two study groups: control group with placebo administration or probiotic administration group.",[36],"2026-02-24",{"date":584,"type":48},"2026-02-25",{"date":586,"type":48},"2024-04-12",{"date":588,"type":23},"2026-12",{"name":590,"class":591},"ProbiSearch SL","INDUSTRY",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":63,"sex":18,"minAge":64,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":67,"phases":602,"briefSummary":603,"conditions":604,"keywords":613,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":206},"100572968","physical-activity-and-community-empowerment-project-100572968","NCT06740162","Physical Activity and Community EmPOWERment Project","A Stage 1 Pilot Test for Feasibility and Efficacy of a Multi-Level Intervention to Increase Physical Activity in Adults With Intellectual Disability: Physical Activity and Community EmPOWERment (PACE)","PACE","Inclusion criteria for adults with ID will include:\n\n* ages 18 and older with a prior clinical diagnosis of ID, confirmed by scores \\\u003C 70 and + 90% on the Leiter-3 International Performance Scales and\u002For an adaptive behavior measure using the Vineland Adaptive Behavior Scales,\n* Medical clearance to participate in moderate-to-vigorous physical activity as determined by the American College of Sports Medicine (ACSM) preparticipation algorithm,\n* Adult does not show clinically elevated symptoms of Alzheimer's Disease (AD)\u002F Alzheimer's Disease and Related Dementias (ADRD) as indicated by a score of \\\u003C 20 on the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities.\n* One caregiver\u002Fguardian is able and willing to participate.\n* must tolerate at least 8 hours of daily wear-time of Actigraph device during initial assessment period (4 of 7 days),\n* must average 20 minutes or less of moderate to vigorous physical activity (MVPA) minutes per day (140 MVPA minutes or less across 7-day period measured during the initial assessment period, and\n* must reside in North Carolina or Arkansas.\n\nExclusion Criteria for adults with ID:\n\n• Diagnosis of AD, dementia, or related disorders. Participants will not be excluded based on gender, race, or ethnicity. There will be no upper age limit due to the heterogeneity of onset of AD\u002FADRD in individuals with ID.\n\nInclusion criteria for coach will include:\n\n* access to the internet and a mobile device,\n* has weekly contact with the adult participant with ID,\n* can converse and read in English to comprehend intervention materials and website content, and\n* must reside in North Carolina or Arkansas\n\nInclusion criteria for caregiver will include:\n\n* ability to converse and read in English to comprehend and answer interview questions, (2) must care for an adult with ID who is willing to participate in the study,\n* must reside in North Carolina or Arkansas, and\n* must attend all study visits with adult with ID.",{"count":601,"type":23},376,[69],"Purpose: Conduct a wait-list randomized controlled trial (RCT) of an inclusive physical activity program called PACE for adults with intellectual disability (ID) who are not yet showing signs of Alzheimer's Disease (AD)\u002Fage-related dementias (ARD).\n\nParticipants: Participants include 120 adults with ID, their caregivers, and their coaches (up to 360 individual participants, grouped as triads), recruited through the University of North Carolina at Chapel Hill and the University of Arkansas. Participants also include 16 exercise professionals.\n\nProcedures (methods): Each cohort will include 20 triads who are randomly assigned to the PACE program or the waitlist control group.",[32,36,107,396,605,606,607,608,609,610,611,612,508],"Fragile X Syndrome","Cri-du-Chat Syndrome","De Lange Syndrome","Mental Retardation, X-Linked","Prader-Willi Syndrome","Rubinstein-Taybi Syndrome","Trisomy 13 Syndrome","WAGR Syndrome",[614,615,616,617,618],"physical activity","intellectual disability","age-associated memory impairment","aging","Alzheimer Disease prevention","2026-02-19",{"date":621,"type":48},"2026-02-23",{"date":623,"type":48},"2025-01-10",{"date":625,"type":23},"2028-06",{"name":627,"class":55},"University of North Carolina, Chapel Hill",{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":361,"maxAge":64,"enrollmentInfo":635,"targetDuration":4,"studyType":67,"phases":637,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":646,"locationsCount":123},"100625721","innovative-methodologies-for-neuroplasticity-in-developmental-age-with-the-use-of-virtual-reality-100625721","NCT07426315","Innovative Methodologies for Neuroplasticity in Developmental Age With the Use of Virtual Reality","M.I.N.E.R.V.A., Metodologie Innovative Per la Neuroplasticità in Età Evolutiva Con l'Uso Della Realtà Virtuale a Scopo Abilitativo","Inclusion Criteria:\n\n* Children and adolescents aged 8 to 18 years\n* Diagnosis of one of the following neurodevelopmental disorders:\n\n  * Attention Deficit Hyperactivity Disorder (ADHD)\n  * Autism Spectrum Disorder (ASD)\n  * Cerebral Palsy (CP)\n* Ability to understand and comply with instructions for the intervention\n* Adequate cognitive, motor, and social skills to participate in the rehabilitation program\n* Informed consent obtained from a parent or legal guardian\n\nExclusion Criteria:\n\n* Children and adolescents younger than 8 or older than 18 years\n* Severe cognitive impairments or intellectual disabilities that prevent participation in the rehabilitation program\n* Diagnosis of conditions not related to the target neurodevelopmental disorders, such as:\n\n  * Major psychiatric disorders (e.g., severe depression, schizophrenia)\n  * Neurological disorders not included in the study (e.g., epilepsy)\n* Severe motor impairments that prevent interaction with the virtual reality platform\n* Uncontrolled medical conditions (e.g., severe cardiovascular, respiratory, or endocrine diseases)\n* Lack of informed consent from a parent or legal guardian\n* Participation in another intervention or study that may interfere with the rehabilitation program\n* Behavioral issues or extreme anxiety that make it impossible to follow instructions or interact with the virtual reality system",{"count":636,"type":23},108,[69],"Neurodevelopmental disorders, such as Cerebral Palsy (CP), Attention-Deficit\u002FHyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), are complex conditions that affect various aspects of children's development. Despite advancements in treatments, conventional rehabilitative interventions tend to focus on specific aspects, often overlooking the holistic needs of the patient. Many of these interventions fail to engage children, who may feel uninvolved or demotivated. Innovative technologies, such as immersive virtual reality (IVR), offer a promising alternative to make rehabilitation more engaging and comprehensive. This study aims to evaluate the effects of IVR-based rehabilitation on children and adolescents with neurodevelopmental disorders, focusing on improvements in cognitive, motor, and social functions. We hypothesize that IVR will enhance social interaction, attention, motor skills, and overall quality of life. The study will include children and adolescents aged 8 to 18 years, diagnosed with ADHD, ASD, and cerebral palsy. The CAR-EN platform, which provides a highly customizable therapeutic environment, will be used. Assessments will measure cognitive, motor, and social skills before and after the intervention. We expect immersive virtual reality to lead to significant improvements in the participants' cognitive, motor, and social abilities. These findings could potentially contribute to a shift in therapeutic guidelines, offering more effective treatments for children with neurodevelopmental disorders.",[36],"2026-02-16",{"date":621,"type":48},{"date":643,"type":48},"2025-08-14",{"date":645,"type":23},"2028-08",{"name":647,"class":55},"IRCCS Centro Neurolesi Bonino Pulejo",{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":653,"acronym":4,"eligibilityCriteria":654,"healthyVolunteers":63,"sex":18,"minAge":24,"maxAge":655,"enrollmentInfo":656,"targetDuration":4,"studyType":67,"phases":657,"briefSummary":658,"conditions":659,"keywords":4,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":666,"locationsCount":4},"100620091","validation-of-the-french-translation-of-the-sosi-m-100620091","NCT07353112","Validation of the French Translation of the SOSI-M","Validation of the French Translation of SOSI-M in Healthy Children and in Children With Mild to Moderate Neurodevelopmental Disorder","For the groupe of children with neurodevelopmental disorders :\n\nInclusion criteria\n\n* neurodevelopmental disorder (NDD)\n* speak french and understand instructions in French\n* and have not been assessed with the SOSI-M in the past 6 months.\n\nExclusion Criteria:\n\n* Severe motor\u002Fcognitive impairment\n* uncorrected visual\u002Fauditory impairment\n* cerebral palsy diagnosis\n\nFor the neurotypical children :\n\nInclusion criteria :\n\n\\- speak french and understand french instructions\n\nExclusion Criteria:\n\n* diagnostic of musculoskeletal condition or neurodevelopmental or neurological condition\n* health condition that contraindicates taking the SOSI-M","14 Years",{"count":578,"type":23},[69],"The aim of this study is to validate the French version of the SOSI-M test on healthy children as well as on children with neurodevelopmental disorders (NDDs).\n\nTherefore, the investigators will conduct a video recording of the test administration on a group of healthy children and on a group of children with NDDs.\n\nThe research question is: Is the French translation of the SOSI-M test equivalent, in terms of functionality and expected results, to the original version for a population of healthy children and children with mild to moderate neurodevelopmental disorders?\n\nThe hypothesis is that the psychometric properties of the French version are similar to those of the original version.\n\nSecondly, the investigators will investigate: Does the difference in socio-cultural context between healthy Belgian and Senegalese children influence the SOSI-M score?\n\nThe hypothesis is that healthy Belgian children obtain better scores compared to healthy Senegalese children.\n\nThe scores of the two groups will be compared with each other and with those obtained in previous studies. Intra- and inter-rater reliability will also be assessed.",[36],"2026-01-15",{"date":662,"type":48},"2026-01-20",{"date":664,"type":23},"2026-02",{"date":445,"type":23},{"name":667,"class":55},"Haute Ecole Ilya Prigogine",{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":674,"eligibilityCriteria":675,"healthyVolunteers":63,"sex":18,"minAge":676,"maxAge":677,"enrollmentInfo":678,"targetDuration":4,"studyType":67,"phases":680,"briefSummary":681,"conditions":682,"keywords":684,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":687,"startDateStruct":689,"completionDateStruct":691,"leadSponsor":693,"locationsCount":123},"100451153","developmental-coordination-disorder-100451153","NCT05154799","Developmental Coordination Disorder","Developmental Coordination Disorder: Role of Perceptual Deficits and Body Representation","DYSENS","Inclusion Criteria:\n\n* Male or female\n* Aged 9 to 11 or 18 to 40\n* Affiliated to a health care organism\n* Signed written informed consent (adult subjects)\n* One of the legal guardians of children subjects providing their free, informed and written consent to participate in the study; With the child also giving orally his consent to participate.\n\nFor participants with Developmental coordination disorder:\n\n* Subjects fulfilling the diagnostic criteria for dyspraxia of DSM-5 (these criteria will be verified by the principal investigator)\n* Total MABC-2 score below the 15th percentile (if this MABC-2 assessment is already available).\n\nExclusion Criteria:\n\n* Prematurity\n* Known neurological pathology (other than dyspraxia)\n* Intellectual disability\n* Visual impairment\n* Surgery or trauma to the upper limbs that has occurred too recently to allow proper testing\n* Subject under tutorship or curatorship\n* Subject deprived of liberty by a judicial or administrative decision\n\nFor healthy volunteers only:\n\n\\- History of developmental coordination disorder in close relatives (parents, children, siblings).","9 Years","40 Years",{"count":679,"type":23},280,[69],"Developmental Coordination Disorder (DCD) corresponds to a clumsiness, a slowness and an inaccuracy of motor performance. This neurodevelopmental disorder affects 6% of school-aged children, and disturbs daily life activities and academic performances. The etiology of DCD is still unknown. An understanding of this disorder is necessary to improve interventions and therefore quality of life of these people.\n\nA deficit of the so-called internal models is the most commonly described hypothesis of DCD. Indeed, children with DCD exhibit difficulties in predictive control. Internal models, useful for motor control, are closely related to the sensory system, as they are elaborated on and constantly fed by sensory feedback. Deficits in sensory performance are described in DCD, mostly in the visual system, which could in turn partly explain poor motor performance. However, visuo-perceptual deficits cannot explain the entire motor difficulties because some activities in daily life, as buttoning a shirt, are often performed without visual control. Although the integrity of proprioceptive and tactile systems is necessary for the building of internal models, and therefore for a stable motor control, these sensory systems have been very little investigated in DCD.\n\nMoreover, using a tool is often disturbed in children with DCD. In neurotypical subjects, tool use induces a plasticity of body representation, as reflected by modifications of movement kinematics after tool use. Proprioceptive abilities are necessary for this update of the body schema. Thus, potential deficits of the proprioceptive system in children with DCD could impair the plastic modification of the body schema, and hence of motor performance, when using a tool. The aim of this study is to identify the main cause of the DCD, both by evaluating the tactile and proprioceptive abilities and by assessing the body schema updating abilities in children with DCD.\n\nWhile some daily life activities improve with age, some motor difficulties persist in adults with DCD. To our knowledge, perceptual abilities have never been investigated in adults with DCD and it is thus unknown whether perceptual deficits are still present in adulthood. This information could allow us to understand if motor difficulties in adult DCD are caused by enduring perceptual deficits and\u002For impaired plasticity of body schema. The second aim of this study is to evaluate abilities of perception and of body schema plasticity in adults with DCD.",[683,36],"Motor Skills Disorders",[685,686],"Healthy subject","Developmental coordination disorder",{"date":688,"type":48},"2026-01-16",{"date":690,"type":48},"2021-12-21",{"date":692,"type":23},"2027-01-21",{"name":694,"class":55},"Hospices Civils de Lyon",{"id":696,"slug":697,"hasResults":12,"nctId":698,"briefTitle":699,"officialTitle":700,"acronym":4,"eligibilityCriteria":701,"healthyVolunteers":63,"sex":18,"minAge":4,"maxAge":434,"enrollmentInfo":702,"targetDuration":434,"studyType":25,"phases":4,"briefSummary":703,"conditions":704,"keywords":708,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":714,"lastUpdatePostDateStruct":715,"startDateStruct":717,"completionDateStruct":719,"leadSponsor":721,"locationsCount":94},"100615699","motor-development-and-early-predictors-of-psychomotor-outcomes-in-preterm-and-term-infants-assessed-by-mos-r-and-caregiver-questionnaire-at-18-and-36-months-100615699","NCT07296003","Motor Development and Early Predictors of Psychomotor Outcomes in Preterm and Term Infants Assessed by MOS-R and Caregiver Questionnaire at 18 and 36 Months","A Longitudinal Observational Study of Early Spontaneous Motor Activity, Postural Control, and Motor Optimality Score (MOS-R) as Predictors of Psychomotor, Cognitive, and Sensory Development at 18 and 36 Months in Preterm and Term Infants, With Consideration of Early Therapeutic Intervention","Inclusion Criteria:\n\n* The child was born either preterm or full-term. Both groups are included in the study.\n* The child completed a video recording of early movements during routine check-ups in the first months of life.\n* The parents or legal guardians agree to participate and give informed consent.\n* The child will be available for follow-up at around 18-36 months of age, when parents will complete a developmental questionnaire.\n\nExclusion Criteria:\n\n* There is no usable video recording of the child's early spontaneous movements from the neonatal or early infant period.\n* The child has a diagnosed medical condition that makes movement assessment impossible (for example, severe congenital anomalies or conditions preventing typical movement).\n* Parents do not wish to participate or withdraw their consent.\n* The child is not available for follow-up, meaning that the developmental questionnaire at 18-36 months cannot be completed.",{"count":578,"type":23},"This study examines how early motor behavior in infants relates to their later psychomotor development. Researchers will observe both preterm and full-term infants during the first months of life, using video-based assessments to evaluate spontaneous movements and early postural control. These early motor patterns will be scored with the Motor Optimality Score - Revised (MOS-R).\n\nWhen the children reach 18 and 36 months of age, their development in areas such as motor skills, communication, sensory processing, and social behavior will be evaluated through a caregiver-completed questionnaire.\n\nThe purpose of the study is to determine whether early motor quality can predict later developmental outcomes, whether preterm and full-term infants with similar motor scores develop differently, and whether early therapy may improve outcomes for infants with low MOS-R results.",[36,683,705,706,707],"Infant, Premature Development","Infant, Term Development","Postural Balance",[709,710,711,712,227,713],"General Movements Assessment","Motor Optimality Score Revised","Postural Control","Full-Term Infants","Neurodevelopmental Outcomes","2026-01-02",{"date":716,"type":48},"2026-01-06",{"date":718,"type":48},"2024-04-19",{"date":720,"type":23},"2027-07-30",{"name":722,"class":55},"Masaryk University",{"id":724,"slug":725,"hasResults":12,"nctId":726,"briefTitle":727,"officialTitle":728,"acronym":4,"eligibilityCriteria":729,"healthyVolunteers":12,"sex":18,"minAge":24,"maxAge":300,"enrollmentInfo":730,"targetDuration":4,"studyType":67,"phases":732,"briefSummary":733,"conditions":734,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":736,"lastUpdatePostDateStruct":737,"startDateStruct":738,"completionDateStruct":740,"leadSponsor":742,"locationsCount":744},"100369906","evaluation-of-effectiveness-of-child-oriented-goal-setting-in-paediatric-rehabilitation-the-engage-approach-100369906","NCT04096430","Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)","Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach): A Pragmatic Cluster Randomized Controlled Trial and Economic Analysis","Inclusion criteria are children with a diagnosed disability who:\n\n1. are between the ages of 5-12 years\n2. are able to engage in the goal-setting process (determined by therapists)\n3. are referred to PT and\u002For OT for a period of direct treatment\n4. speak English.\n\nChildren will be excluded from the trial if:\n\n1. the parent or guardian who attends therapy does not speak English\n2. the child has a diagnosis that suggests developmental regression\n3. the child has uncontrolled seizures (i.e., seizure within the past 2 months).",{"count":731,"type":23},96,[69],"Children with disabilities often access rehabilitation services to improve their abilities to participate in everyday activities. Goal-directed therapy is considered an important therapeutic strategy to achieve outcomes that are meaningful to families. Not a lot is known about the effects of goal setting on rehabilitation outcomes. Strategies to help children participate in the goal-setting process are rarely used in clinical practice. The aim of this project is to test the effects of a child-focussed goal setting approach, Enhancing Child Engagement in Goal Setting (ENGAGE), on therapy outcomes. Service use and the cost vs. benefits of the ENGAGE approach compared to usual practice will also be examined. Children with neurodevelopmental disabilities aged 5-12 years old (n=96) who access paediatric rehabilitation services at six rehabilitation sites will participate. Therapists (n=24) at participating sites in Alberta, Canada will be randomized into 1) the ENGAGE intervention group or 2) the usual therapy practice control group. Children will participate in the ENGAGE approach to goal setting or usual practice based on the allocation of their therapist. This study will determine if the ENGAGE approach to goal setting affects child goal performance, satisfaction with goal performance, functional abilities, participation, and parent and child quality of life. The investigators will also evaluate differences in parent and child quality of life in relation to parent costs (e.g., absenteeism, presenteeism, travel costs) and compare amount of therapy time between the two groups to see which approach is more cost-effective and efficient. After the study, children, parents and therapists will be asked to discuss aspects that influenced effective implementation of the ENGAGE approach. This study could provide evidence to improve meaningful child and family outcomes in paediatric rehabilitation and improve efficiency of paediatric rehabilitation services.",[107,36,735],"Cerebral Palsy","2025-12-31",{"date":716,"type":48},{"date":739,"type":48},"2022-03-01",{"date":741,"type":23},"2026-05-31",{"name":743,"class":55},"University of Alberta",6]